844442-38-2

Basic information

• Product Name: 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl1H-pyrazole-3-carboxamide
• Synonyms: 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl1H-pyrazole-3-carboxamide;N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide;4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide;AT 7519 N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide;N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide AT 7519;AT7519, >=99%
• CAS NO: 844442-38-2
• Molecular Formula: C₁₆H₁₇Cl₂N₅O₂
• Molecular Weight: 382.24448
• Product Categories: Inhibitors
• Mol File: 844442-38-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 586 °C at 760 mmHg
• Flash Point: 308.2 °C
• Appearance: /
• Density: 1.48 g/cm³
• Solubility: insoluble in H2O; ≥3.99 mg/mL in EtOH with ultrasonic; ≥9.55 mg/mL in DMSO with gentle warming
• PKA: 11.10±0.70(Predicted)
• CAS DataBase Reference: 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl1H-pyrazole-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl1H-pyrazole-3-carboxamide(844442-38-2)
• EPA Substance Registry System: 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl1H-pyrazole-3-carboxamide(844442-38-2)

Safety Data

• Hazardous Substances Data: 844442-38-2(Hazardous Substances Data)

Usage

Biological Activity

at7519 is a small-molecule inhibitor of cyclin-dependent kinases (cdks) with ic50 values of 210, 47, 100, 13, 170 and <10 nm for cdk1, cdk2, cdk4, cdk5, cdk6 and cdk9, respectively [1].at7519 showed no inhibition activity against cdk3, 7 and other non-cdk kinases. it inhibited cdk1 in an atp- competitive manner with ki value of 38 nm. at7519 potently inhibited the proliferation of various human tumor cell lines and this activity is cell cycle related. at7519 was also effective in cell lines with p53 mutants or suppression, suggesting that the anti-proliferation efficacy is p53-independent. in hct116 cells, 24 h-treatment of at7519 resulted in a remarkable induction of g0-g1 and g2-m cell cycle arrest. besides that, at7519 at concentrations relating to ic50 induced cell apoptosis (24 h) in hct116, a2780 and ht29 cells with 52%, 3% and 94% survival, respectively. moreover, in hct116 tumor-bearing mice, 10 mg/kg at7519 with intraperitoneal injection caused inhibition of npm phosphorylation and induced apoptosis [1, 2].

references

[1] squires m s, feltell r e, wallis n g, et al. biological characterization of at7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. molecular cancer therapeutics, 2009, 8(2): 324-332.[2] wyatt p g, woodhead a j, berdini v, et al. identification of n-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1 h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design?. journal of medicinal chemistry, 2008, 51(16): 4986-4999.

InChI:InChI=1S/C16H17Cl2N5O2.ClH/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9;/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24);1H

Upstream product

• 844443-80-7 4-[(4-nitro-1H-pyrazole-3-carbonyl)amino]piperidine-1-carboxylic acid tert-butyl ester 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 844443-90-9 tert-butyl 4-(4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamido)piperidine-1-carboxylate 
• 123-91-1 1,4-dioxane 
• 902135-91-5 AT7519 

Relevant articles and documents

Tartaric acid addition salt of 3,4-disubstituted 1H-pyrazole compound and crystal form thereof

The invention provides one or more pharmaceutical composition of 4-(2,6-dichloro-benzoyl) amino)-1H-pyrazole-3-formate piperidine-4-yl-acyl tartaric acid addition salt, a crystallization form of the tartaric acid addition salt and use of the tartaric acid

PHARMACEUTICAL COMBINATIONS

The invention provides combinations of an ancillary compound of the formula (0): and a compound of the formula (I'): Also provided are crystalline forms of the constituent compounds, methods for making them and their uses in treating cancers.

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.